Modeyso
(Dordaviprone (ONC201))Phase 3Small molecule
Modeyso is one of 114 small molecule programs targeting Glioma. It is currently in Phase 3.
3
Indications
5
Total Trials
1
Active Trials
113
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
7
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
514 competitors in Glioblastoma
#DrugCompanyPhaseTrials
1Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Ceenu
AAzurity Pharmaceuticals
Phase 3
Gleevec
NovartisPhase 3
Cymbalta
Alnylam PharmaceuticalsPhase 3
Scemblix
NovartisPhase 3
Lexapro
AbbViePhase 3
Sprycel
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Zejula
GGlaxo Dba Glaxosmithkline
Phase 3
Feraheme
AAzurity Pharmaceuticals
Phase 3
Droxia
TTheravia
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Glioma3 trials
Regulatory
FDA Approval Timeline[4]
Aug 6, 2025
MODEYSO
NDA NDA219876
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dordaviprone (ONC201). EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]